Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
ADMA Biologics (ADMA) has issued an announcement.
ADMA Biologics, Inc. has made key decisions regarding executive compensation, including approving a substantial base salary and performance-related cash bonuses for CEO Adam Grossman, reflecting overachievement of 2023’s corporate goals. Additionally, the Board, on the advice of the Compensation Committee, has set equity grants for non-employee directors and ownership guidelines to strengthen vested interests in the company. In a notable transition, CFO Brian Lenz will move to a consultancy role, with a search for his full-time successor underway and CEO Grossman taking on interim CFO duties.
Learn more about ADMA stock on TipRanks’ Stock Analysis page.
